Company intelligence / Profile preview

Vector Group

Basel, Switzerland

Ownership: Private
Employees: ~40
Development stage: Other

Overview

Developing a precision gene delivery platform using high-capacity virus-like particles with designed adapter proteins for tissue-specific delivery of large genetic cargo, with plans for technical proof-of-concept data in immuno-oncology and genome editing in 2022 and in vivo data for lead programs in early 2023.[1]

Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Vector Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vector Group.

Explore the full profile